The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index; 19 of the 30 sources its claims cite were checked for support.
Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning
Open accessAbstract
Background: Alzheimer’s disease is a prevalent disease with a heavy global burden. Proteomics is the systematic study of proteins and peptides to provide comprehensive descriptions. Aiming to obtain a more accurate and convenient clinical diagnosis, researchers are working for better biomarkers. Urine is more convenient which could reflect the change of disease at an earlier stage. Thus, we conducted a cross-sectional study to investigate novel diagnostic panels. Methods: We firstly enrolled participants from China-Japan Friendship Hospital from April 2022 to November 2022, collected urine samples, and conducted an LC–MS/MS analysis. In parallel, clinical data were collected, and clinical examinations were performed. After statistical and bioinformatics analyses, significant risk factors and differential urinary proteins were determined. We attempt to investigate diagnostic panels based on machine learning including LASSO and SVM. Results: Fifty-seven AD patients, 43 MCI patients, and 62 CN subjects were enrolled. A total of 3366 proteins were identified, and 608 urine proteins were finally included in the analysis. There were 33 significantly differential proteins between the AD and CN groups and 15 significantly differential proteins between the MCI and CN groups. AD diagnostic panel included DDC, CTSC, EHD4, GSTA3, SLC44A4, GNS, GSTA1, ANXA4, PLD3, CTSH, HP, RPS3, CPVL, age, and APOE ε4 with an AUC of 0.9989 in the training test and 0.8824 in the test set while MCI diagnostic panel included TUBB, SUCLG2, PROCR, TCP1, ACE, FLOT2, EHD4, PROZ, C9, SERPINA3, age, and APOE ε4 with an AUC of 0.9985 in the training test and 0.8143 in the test set. Besides, diagnostic proteins were weakly correlated with cognitive functions. Conclusions: In conclusion, the procedure is convenient, non-invasive, and useful for diagnosis, which could assist physicians in differentiating AD and MCI from CN.
Overview
CoChat Summary
TL;DR
This cross-sectional urine proteomics and machine-learning study identified candidate diagnostic panels that distinguished AD and MCI from cognitively normal controls, with test-set AUCs of 0.8824 for AD and 0.8143 for MCI. The panels combined urinary proteins with age and APOE ε4 status, though diagnostic proteins correlated only weakly with cognitive tests.
Key findings
- In 57 AD, 43 MCI, and 62 CN participants, LC-MS/MS identified 3,366 urine proteins; 608 detected in >50% of samples were analyzed. There were 33 differential proteins between AD and CN (21 upregulated, 12 downregulated) and 15 between MCI and CN (7 upregulated, 8 downregulated).
- The AD diagnostic panel included DDC, CTSC, EHD4, GSTA3, SLC44A4, GNS, GSTA1, ANXA4, PLD3, CTSH, HP, RPS3, CPVL, age, and APOE ε4; it achieved an AUC of 0.8824 in the test set.
- The MCI diagnostic panel included TUBB, SUCLG2, PROCR, TCP1, ACE, FLOT2, EHD4, PROZ, C9, SERPINA3, age, and APOE ε4; it achieved an AUC of 0.8143 in the test set.
- EHD4 was selected for both panels; GSTA1 was downregulated in both AD and MCI, while EHD4 and C9 were upregulated in both. Diagnostic proteins were mostly weakly correlated with cognitive tests; HP, TUBB, and FLOT2 showed no significant correlations.
Methods
- Cross-sectional study at China-Japan Friendship Hospital (April–November 2022) enrolling 162 participants >50 years: 57 AD, 43 MCI, 62 CN. Clinical history, neuropsychological battery, APOE genotype, and qEEG/MRI in most were collected; midstream urine was analyzed by LC-MS/MS in DDA mode.
- Label-free quantification used iBAQ/FOT; proteins detected in >50% of samples were retained (608), with missing values imputed by KNN. Differential proteins used limma with p < 0.05 and |log2FC| > 0.58; PPI, GO, and GSEA analyses were performed.
- LASSO selected proteins plus age and APOE ε4; SVM classifiers with tenfold cross-validation compared linear, polynomial, radial, and sigmoid kernels; data were split 0.7 training/0.3 test, with accuracy and AUC evaluated.
Limitations
- Paper-stated: single-site sample with no multi-hospital/community real-world validation; relatively few proteins detected in >50% of samples; no in vivo or in vitro experiments on mechanisms; machine-learning feature selection used differential proteins derived from the whole dataset, so test-set performance may be optimistic and some results may be coincidental.
- Evident from the text: the cross-sectional design cannot establish temporal or causal relationships; the sample size is modest and groups differ in age and APOE ε4 distribution, which may affect comparisons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
18 Valid · 0 Not valid · 8 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Early detection of MCI could suggest an elevated risk for AD, and early comprehensive interventions could stop or postpone the progression of MCI to dementia [4].”
§ Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning > Background
What the sources say
- Partly supportedcites [4] Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA. 2014;312(23):2551–61. sourceExperimental — accuracy not yet measured
The Prognosis section says MCI can indicate a risk of progression to Alzheimer’s dementia, but individual risk cannot be predicted confidently. The Future Directions section describes currently available interventions as having limited efficacy in preventing or delaying progression; it does not support the claim that early comprehensive interventions could stop it. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“while the difference between MCI patients and healthy controls or AD did not reach statistical significance [64].”
§ Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning > Discussion
What the sources say
- Supportedcites [64] Zhu Y, Chen Z, Chen X, Hu S. Serum sEPCR levels are elevated in patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2015;30(5):517–21. source
The Results (p. 2) report no statistically significant difference in serum sEPCR levels between MCI patients and healthy controls (P = .055), or between MCI and AD patients (P = .054). (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The most accurate way to quantify pathological accumulation in a live brain is using PET imaging, but its expense and complexity prevent it from becoming widely used [11].”
§ Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning > Background
What the sources say
- Partly supportedcites [11] Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, et al. Developing novel blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement. 2014;10(1):109–14. sourceExperimental — accuracy not yet measured
The Introduction describes PET among expensive and/or invasive biomarker approaches and calls for less costly, more widely available blood-based biomarkers. It does not say that PET's complexity prevents widespread use, or establish the citing sentence's claim that PET is the most accurate way to quantify pathological accumulation in a living brain. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were 33 significantly differential proteins between the AD and CN groups and 15 significantly differential proteins between the MCI and CN groups.”
§ Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were 33 significantly differential proteins between the AD and CN groups and 15 significantly differential proteins between the MCI and CN groups.”
§ Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning > Abstract
plainstates an associationn = 43- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
20 more claims
Create a free account to see all 71 claims and every source verdict.
- Probably not a substantial claim. 40
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In early diagnosis, various biomarkers of CSF, blood, urine,610 saliva,611 and retina,612 may contribute to comprehensively reflecting the AD pathological process, serving as potential auxiliary tools that are more convenient, cost-effective, or less invasive.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [610]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning > Abstract
“AD diagnostic panel included DDC, CTSC, EHD4, GSTA3, SLC44A4, GNS, GSTA1, ANXA4, PLD3, CTSH, HP, RPS3, CPVL, age, and APOE ε4 with an AUC of 0.9989 in the training test and 0.8824 in the test set”
§ Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning > Evaluation of diagnostic value based on the SVM model
“Radial achieved the highest predictive value with an accuracy of 0.9881, an F1 measure of 0.9876, and an AUC of 0.9739 in the AD-CN group”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning > Conclusions
“D Volcano plot shows the distribution of all proteins between AD and CN.”
§ Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning > Conclusions
“C Heatmap of a total of 15 differential proteins between MCI and CN.”
Citations
Cites
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · cited 1×
“Differential urinary proteins were filtered utilizing limma package [30] with a threshold of p < 0.05 and the absolute value of log2 fold change (log2FC) > 0.58 after log 2 transformation and normalization.”
MethodInfluentialclusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259 · cited 1×
“…to investigate various GO terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that might be related with AD or MCI when compared to CN in all proteins. clusterProfiler package [34, 35] was utilized for enrichment analysis while enrichplot package [36] was utilized for visualization.”
MethodMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 2×
“Based on core clinical criteria for AD dementia, the patients are classified into probable AD dementia and possible AD dementia in clinical practice [5].”
MethodclusterProfiler 4.0: A universal enrichment tool for interpreting omics data
(2021) · doi:10.1016/j.xinn.2021.100141 · Cited by 12,455 · cited 1×
“…to investigate various GO terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that might be related with AD or MCI when compared to CN in all proteins. clusterProfiler package [34, 35] was utilized for enrichment analysis while enrichplot package [36] was utilized for visualization.”
MethodNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“MCI is defined with the 2011 NIA-AA diagnostic criteria [22], as the following shows: (1) concern about a cognition decline compared with the previous status, reported by the patient himself, the informant, or a skilled physician; (2) decline in at least one cognitive domain after age and education…”
MethodGlobal quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 1×
“Protein quantification was carried out using the intensity-based absolute quantification (iBAQ) algorithm [28].”
MethodNichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Self-citationScheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Fluid-based biomarkers for neurodegenerative diseases
Cao, Y., Xu, Y., Cao, M., Chen, N., Zeng, Q., Lai, M. K. P., Fan, D., Sethi, G., & Cao, Y. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102739 · Cited by 68
Yarbro, J. M., Shrestha, H. K., Wang, Z., Zhang, X., Zaman, M., Chu, M., Wang, X., Yu, G., & Peng, J. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00874-5 · Cited by 46
“Urine proteomics also showed potential for AD biomarker discovery [178]: a recent study identified 13-protein diagnostic panel with high diagnostic accuracy [179].”
Self-citationAfrin, M. R., Upadhyaya, P. G., Hashim, A., Bhattacharya, K., Chanu, N. R., Das, D., Khanal, P., & Deka, S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102736 · Cited by 28
Wang, H., Li, J., Tu, W., Wang, Z., Zhang, Y., Chang, L., Wu, Y., & Zhang, X. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240301 · Cited by 15
Self-citation
Metadata
- Authors
- Wang, Y., Sun, Y., Wang, Y., Jia, S., Qiao, Y., Zhou, Z., Shao, W., Zhang, X., Guo, J., Zhang, B., Niu, X., Wang, Y., & Peng, D.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- China-Japan Friendship Hospital (CN)
- Peking University (CN)
- Corresponding author
- Wang, Yu
- Wang, Yi
- Peng, Dantao
- Venue
- Alzheimer's Research & Therapy
- Published
- 2023-11-04
- Volume
- 15
- Issue
- 1
- Pages
- 191-191
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC10625308
- OpenAlex
- W4388341887
- Cited by
- 34
- References
- 64
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 8
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Key Research and Development Program of China (2018YFA0507503, 2022YFC2010103)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- Alzheimer's disease, mild cognitive impairment, urine proteomics, diagnostic biomarkers, diagnostic panel, APOE ε4, non-invasive diagnosis, machine learning classification, LASSO, support vector machine
- MeSH terms
- Machine Learning, Alzheimer Disease, Chromatography, Liquid, Cross-Sectional Studies, Humans, Biomarkers, Proteomics, Apolipoprotein E4, Tandem Mass Spectrometry, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning. https://app.cochat.ai/papers/10.1186/s13195-023-01324-4
- The paper
- Wang, Y., Sun, Y., Wang, Y., Jia, S., Qiao, Y., Zhou, Z., Shao, W., Zhang, X., Guo, J., Zhang, B., Niu, X., Wang, Y., & Peng, D. (2023). Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-023-01324-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.